Englander Institute for Precision Medicine

Publications

Found 692 results
Author Title Type [ Year(Asc)]
2018
Cai L, Tsai Y-H, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM et al..  2018.  ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.. Mol Cell. 72(2):341-354.e6.
2017
Shukla S, Cyrta J, Murphy DA, Walczak EG, Ran L, Agrawal P, Xie Y, Chen Y, Wang S, Zhan Y et al..  2017.  Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance.. Cancer Cell. 32(6):792-806.e7.
Rickman DS, Beltran H, Demichelis F, Rubin MA.  2017.  Biology and evolution of poorly differentiated neuroendocrine tumors.. Nat Med. 23(6):1-10.
Sailer V, Gevensleben H, Dietrich J, Goltz D, Kristiansen G, Bootz F, Dietrich D.  2017.  Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.. PLoS One. 12(6):e0179412.
Dutta A, Panja S, Virk RK, Kim JYeji, Zott R, Cremers S, Golombos DM, Liu D, Mosquera JMiguel, Mostaghel EA et al..  2017.  Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.. Eur Urol. 72(4):499-506.
Sailer V, Holmes EEva, Gevensleben H, Goltz D, Dröge F, Franzen A, Dietrich J, Kristiansen G, Bootz F, Schröck A et al..  2017.   DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.. Clin Epigenetics. 9:12.
Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.  2017.  DNA Repair in Prostate Cancer: Biology and Clinical Implications.. Eur Urol. 71(3):417-425.
Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA.  2017.  The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.. Eur Urol. 71(2):237-246.
Pauli C, Moch H, Rubin MA.  2017.  [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].. Pathologe. 38(Suppl 2):160-168.
Romanel A, Zhang T, Elemento O, Demichelis F.  2017.  EthSEQ: ethnicity annotation from whole exome sequencing data.. Bioinformatics. 33(15):2402-2404.
Huang FW, Mosquera JMiguel, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD et al..  2017.  Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations.. Cancer Discov. 7(9):973-983.
Minciacchi VR, Zijlstra A, Rubin MA, Di Vizio D.  2017.  Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed? Prostate Cancer Prostatic Dis. 20(3):251-258.
Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA et al..  2017.  A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.. Cold Spring Harb Mol Case Stud. 3(5)
Dhingra P, Martinez-Fundichely A, Berger A, Huang FW, Forbes ANeil, Liu EMinwei, Liu D, Sboner A, Tamayo P, Rickman DS et al..  2017.  Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.. Genome Biol. 18(1):141.
Romanel A, Garritano S, Stringa B, Blattner M, Dalfovo D, Chakravarty D, Soong D, Cotter KA, Petris G, Dhingra P et al..  2017.  Inherited determinants of early recurrent somatic mutations in prostate cancer.. Nat Commun. 8(1):48.
Imielinski M, Guo G, Meyerson M.  2017.  Insertions and Deletions Target Lineage-Defining Genes in Human Cancers.. Cell. 168(3):460-472.e14.
Lee D, Fontugne J, Gumpeni N, Park K, MacDonald TY, Robinson BD, Sboner A, Rubin MA, Mosquera JM, Barbieri CE.  2017.  Molecular alterations in prostate cancer and association with MRI features.. Prostate Cancer Prostatic Dis. 20(4):430-435.
Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017
Sailer V, Pauli C, Merzier EC, Mosquera JMiguel, Beltran H, Rubin MA, Rao RA.  2017.  On-site Cytology for Development of Patient-Derived Three-dimensional Organoid Cultures - A Pilot Study.. Anticancer Res. 37(4):1569-1573.
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
Uhl B, Gevensleben H, Tolkach Y, Sailer V, Majores M, Jung M, Meller S, Stein J, Ellinger J, Dietrich D et al..  2017.  PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.. J Mol Diagn. 19(1):107-114.
Poran A, Nötzel C, Aly O, Mencia-Trinchant N, Harris CT, Guzman ML, Hassane DC, Elemento O, Kafsack BFC.  2017.  Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites.. Nature. 551(7678):95-99.
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z et al..  2017.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.. Science. 355(6320):84-88.
Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V et al..  2017.  SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.. Cancer Cell. 31(3):436-451.
Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, Le Magnen C, Chester D, Mostaghel EA, Califano A et al..  2017.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.. Cancer Discov. 7(7):736-749.